Tevard Biosciences
PrivateLast Round
VC Round
May 20, 2026
Total Funding Raised
$5M
Company Overview
Tevard Biosciences operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a VC Round in May 2026.
Tevard Biosciences is a biotechnology company that develops tRNA-based gene therapies to treat rare and severe genetic diseases by restoring functional proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tevard Biosciences Comparables
Compare Tevard Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alltrna | 94% | |
| Shape Therapeutics | 79% | |
| Cloverleaf Bio | 76% |
For institutional investors. Book with your work email.
Tevard Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 20, 2026 | ||||
| Convertible Debt | Dec 3, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tevard Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Good Growth Capital | Series A |
| CureDuchenne Ventures | VC Round, Series A |
| Sherpa Healthcare Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 17, 2025
Presented compelling full-length protein rescue data at the 2025 FEBS Special Meeting.
- Nov 17, 2025
Presented data at the 2025 FEBS Special Meeting.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 23, 2026
In Oct '26, Tevard Biosciences, Inc. is developing suppressor tRNAs intended to recognize nonsense mutations, deliver the appropriate amino acid, and enable production of full-length protein.
For institutional investors. Book with your work email.
Tevard Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tevard Biosciences's valuation, stock price, and market status.
Is Tevard Biosciences a public or private company?
Tevard Biosciences is a private company.
What is the current stock price of Tevard Biosciences?
Tevard Biosciences is a private company, so its shares have no public market price. Caplight tracks Tevard Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tevard Biosciences worth (valuation)?
Valuation information for Tevard Biosciences is not publicly available.
Can I buy Tevard Biosciences stock?
Tevard Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tevard Biosciences's last funding round?
Tevard Biosciences's most recent funding round was VC Round on May 20, 2026.
Who are the main investors in Tevard Biosciences?
Key investors in Tevard Biosciences include Good Growth Capital, CureDuchenne Ventures, Sherpa Healthcare Partners.
Will Tevard Biosciences IPO soon?
No public IPO plans have been announced for Tevard Biosciences.
How can I track Tevard Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Tevard Biosciences's shares on secondary markets.